EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia

Vincent Daniels iD, Kunal Saxena, Oscar Patterson-Lomba, Andres Gomez-Lievano iD, Jarir At Thobari, Nancy Durand iD, Evan Myers

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0310591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Vincent Daniels und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co, Rahway, NJ, United States of America. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Cost-Benefit Analysis, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent evidence suggests that 1 dose of the human papillomavirus (HPV) vaccine may have similar effectiveness in reducing HPV infection risk compared to 2 or 3 doses.

Objective

To evaluate the public health impact and cost-effectiveness of implementing a 1-dose or a 2-dose program of the 9-valent HPV vaccine in a low- and middle-income country (LMIC).

Methods

We adapted a dynamic transmission model to the Indonesia setting, and conducted a probabilistic sensitivity analysis using distributions reflecting the uncertainty in levels and durability of protection of a 1-dose that were estimated under a Bayesian framework incorporating 3-year vaccine efficacy data from the KEN SHE trial (base-case) and 10 year effectiveness data from the India IARC study (alternative analysis). Scenarios included different coverage levels targeted at girls-only, or girls and boys. Costs and benefits were computed over 100 years from a national single-payer perspective.

Results

Depending on the coverage and target population, the median number of cancer cases avoided in 2-dose programs ranged between 600,000–2,100,000, compared to 200,000–600,000 in 1-dose programs. The 1-dose programs are unlikely to be cost-effective compared to 2-dose programs even at low willingness-to-pay (WTP) thresholds. The girls-only 2-dose program tends to be cost-effective at lower WTP thresholds, particularly in scenarios with high coverage, dose price and discount rate, while the girls and boys 2-dose program is cost-effective at higher WTP thresholds. In the alternative analysis, 1-dose programs have higher probability of being cost-effective compared to the base-case, particularly for low WTP thresholds (less than 0.5 GDP) and for high coverage, dose price and discount rate.

Conclusion

Adoption of 1-dose programs with 9-valent vaccine in an LMIC resulted in more vaccine-preventable HPV-related cancer cases than 2-dose programs. The 2-dose programs were more likely to be cost-effective than 1-dose programs for a wide range of WTP thresholds and scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesCost-Benefit AnalysisPapillomavirus InfectionsHumansIndonesiaFemaleAdolescentMaleDeveloping CountriesUterine Cervical NeoplasmsImmunization ProgramsVaccinationBayes TheoremChildHuman Papillomavirus Viruses

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Merck & Co, Rahway, NJ, United States of America.
  • Analysis Group, Inc., Boston, MA, United States of America.
  • Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America.

ORCID-Profile: Vincent Daniels, Andres Gomez-Lievano, Nancy Durand

Förderung

  • Merck

Zitieren

APA

Daniels, V., Saxena, K., Patterson-Lomba, O., Gomez-Lievano, A., At Thobari, J., Durand, N., & Myers, E. (2024). Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia. PLOS ONE. https://doi.org/10.1371/journal.pone.0310591

Vancouver

Daniels V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, At Thobari J, Durand N, et al. Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia. PLOS ONE. 2024. doi:10.1371/journal.pone.0310591

BibTeX
@article{Daniels2024,
  author = {Daniels, Vincent and Saxena, Kunal and Patterson-Lomba, Oscar and Gomez-Lievano, Andres and At Thobari, Jarir and Durand, Nancy and Myers, Evan},
  title = {Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0310591}
}
Kostenlos starten →